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Introduction {#sec005}
============

*Streptococcus pneumoniae* (*Sp*) is a leading cause of bacterial pneumonia, meningitis, and sepsis and a major source of morbidity and mortality worldwide\[[@pone.0201312.ref001]\]. Although pneumococcal vaccines help prevent pneumococcal disease, the WHO estimates that approximately 1 million children die of pneumococcal disease every year, mostly in developing countries\[[@pone.0201312.ref002], [@pone.0201312.ref003]\]. Although global estimates are valuable, national public health officials need country and region-specific estimates of disease incidence and prevalence for policy decision making\[[@pone.0201312.ref004]\]. To date, China has lacked substantial, high quality surveillance systems to measure incidence of *Sp* infection associated with respiratory disease and meningitis.

Bacterial culture from blood or cerebrospinal fluid is the established method of diagnosing invasive *Sp* infection\[[@pone.0201312.ref005]\], but bacterial culture is infrequently used in China hospitals. Additionally, patients in China frequently take antibiotics by self-purchased before seeking medical care\[[@pone.0201312.ref006]\], potentially resulting in false negatives for *Sp* culture. The above factors make it challenging to estimate the burden of *Sp* infections in China.

In April 2010, the Chinese Center for Disease Control and Prevention (China CDC), in collaboration with the United States Centers for Disease Control and Prevention (US CDC), launched active surveillance for severe acute respiratory infection (SARI) and meningitis in Jingzhou city, Hubei province. The aim of this project was to characterize etiologies of SARI and meningitis in people admitted with these conditions to Jingzhou City hospitals. We analyzed data from this surveillance system to describe the epidemiology and clinical characteristics of SARI and meningitis patients with *Sp* infections.

Methods {#sec006}
=======

We conducted surveillance in three general hospitals and one pediatric hospital in Jingzhou City, Hubei Province located in central China as previously described\[[@pone.0201312.ref007]\]. We collected demographic, clinical, and outcome data for all enrolled hospitalized patients with severe acute respiratory infection (SARI) or meningitis. Additionally, we obtained blood, urine, and cerebrospinal fluid (CSF) samples to test for *Sp* infections between April 5, 2010 and September 30, 2012.

Case definitions {#sec007}
----------------

Patients met the case definition for SARI if they were hospitalized and had: temperature ≥37.3°C and at least one of the following: cough, sore throat, tachypnea, difficulty breathing, abnormal breath sounds on auscultation, sputum production, hemoptysis, chest pain, or chest radiograph consistent with pneumonia. Patients met the case definition for meningitis if they were hospitalized and had: temperature ≥37.3°C and change in mental status, meningeal irritation signs (positive Kernig's or Brudzinski's signs), bulging fontanelle (if aged \<12 months), toxic appearance, petechial rash, or purpural rash. Patients were excluded from the study if they were infants who were born in the hospital and became ill while hospitalized.

A case was defined as laboratory-confirmed for *Sp* if it had a blood, urine (≥18 years), or CSF specimen that was positive for *Sp* by bacterial culture or antigen testing.

Data collection {#sec008}
---------------

Physicians screened potential cases for SARI or meningitis at hospital admission, after obtaining verbal consent, or proxy consent (for children), physicians reviewed patients' medical records to obtain demographic information, past medical history including records on vaccinations, antibiotics use before hospitalization, clinical signs and symptoms, and radiographic results on a structured case report form. After discharge, physicians were also requested to update the case report form to complete data about treatment, disease outcomes and laboratory testing results. Patients were followed up to collect outcomes at 30 days after discharge.

Specimen collection and testing {#sec009}
-------------------------------

For SARI patients, nurses collected whole blood specimens and urine specimens (≥18 years) within two hours of enrollment or before the use of antibiotics following standardized procedures. Whole blood specimens (10ml for patients aged \>15 years; 4 ml for those aged 7--14 years; 3 ml for those aged 3--7 years; 1 ml for those aged \<3 years) were collected and then transferred to a hospital clinical laboratory within two hours to culture by BD-9050 automated culture system for *Sp*. For all SARI patients aged \>18 years, nurses collected 10 ml of urine to detect *Sp* antigen. Urine specimens were tested by the Binax NOW *Streptococcus pneumoniae* urinary antigen test per the manufacturer's instructions. For meningitis patients, the collection and testing of blood samples was the same as for SARI patients. Cerebrospinal fluid (CSF) was obtained within two hours of enrollment or before initiation of antibiotic treatment following standard procedures for lumbar puncture; 40 µl of CSF was inoculated into bacterial culture within one hour of collection. For *Sp* isolates, PCR was used to determine serotype using previously published methods\[[@pone.0201312.ref008]\].

Data analysis {#sec010}
-------------

Data were entered into Epidata software (version 3.1) and imported into SPSS (v17.0, SPSS, Chicago, IL, USA) for analysis. To describe baseline characteristics, clinical, treatment, complication, and outcome, we conducted frequency analyses for categorical variables and estimated median and interquartile ranges (IQRs) for continuous variables. Patients with laboratory-confirmed *Sp* were divided into age groups (\<5 years, 5--64 years group, and aged ≥65 years) and compared using chi-squared test and Fisher's exact test to compare categorical variables, and *t*-test to compare continuous variables; all statistical tests were two-sided with *p*\<0.05.

Human subjects review {#sec011}
---------------------

This project was approved by the ethical review committees at the Chinese Center for Disease Control and Prevention (China CDC, Beijing, China) and the U.S. Centers for Disease Control and Prevention (US CDC, Atlanta, GA, USA). In response to the 2009 H1N1 pandemic, in October 2009 China's Ministry of Health issused the national surveillance protocal for SARI and authorized participating hospitals to collect individual case data and specimens from SARI patients. Therefore, for SARI patients in this study, participation only required patients or their parent/guardian to provide brief verbal consent. Blood culture and lumbar puncuture for suspected meningitis are the routine clinical practice in hospitals, consent in China for such procedures is almost always verbal, not written.

Results {#sec012}
=======

A total of 22,608 hospitalized patients in the four surveillance hospitals met either the SARI or meningitis case definitions from April 5, 2010 to September 30, 2012. Two hundred and thirty three (n = 233) refused to participate. We enrolled 22,375 total patients: 22,202 (99%) SARI and 173 (1%) meningitis.

Patient characteristics {#sec013}
-----------------------

Twelve thousand eight hundred and forty two (12,842, 58%) SARI patients and 98 (57%) meningitis patients were male, and the median age was 2 years (interquartile range: 1--4) and 28 years (interquartile range: 8--46) for SARI and meningitis, respectively. Children aged \< 5 years accounted for 79% of SARI patients while meningitis patients were most often aged 15--49 years (46%). About 1,316 (6%) SARI patients and 15 (9%) meningitis patients had at least one chronic disease, including hypertension (2%), chronic obstructive pulmonary disease (1%), chronic bronchitis (1%) and asthma (1%); hypertension (4%) and asthma (1%) were the chronic diseases most common in meningitis patients. Additionally, 19 SARI and 3 meningitis patients were pregnant.

Compared with meningitis patients, SARI cases were more frequently obese (21% vs 4%, p\<0.001). Few patients were vaccinated with 7-valent pneumococcal conjugate vaccine (PCV 7) (3%), 23-valent pneumococcal polysaccharide vaccine (4%), and seasonal influenza vaccine (12%). ([S1 Table](#pone.0201312.s001){ref-type="supplementary-material"})

Laboratory testing {#sec014}
------------------

Overall, 118 (3%, 118/3868) patients with either SARI or meningitis were *Sp* positive: 32 (0.8%, 32/3819) *Sp* from blood/CSF culture and 87 (5%, 87/1735) *Sp* from urine antigen testing. ([Fig 1](#pone.0201312.g001){ref-type="fig"}). Among 2,116 SARI patients aged ≥18 years, blood culture was performed for 1,945 (92%), urine antigen testing for 1,735 (82%), and both methods for 1,680 (79%). *Sp* was recovered from 11 blood cultures (0.6%, 11/1945), and urine antigen testing detected *Sp* in 87 (5%, 87/1735); only 1 patient was *Sp* positive by both blood culture and urine antigen test. Among the 20,086 SARI patients aged \<18 years, only 1,721 (9%) patients were tested by blood culture (other patients were not collected blood), and *Sp* was recovered from 11 (0.6%). Among the 173 meningitis patients, 144 (83%) patients were tested by blood culture, 124 (72%) patients by CSF culture, and 116 (67%) by both. *Sp* was recovered from 6 blood cultures (4%, 6/144), and 7 CSF cultures (6%, 7/124); three patients had both blood and CSF cultures positive for *Sp*.

![Enrollment of patients with SARI and meningitis, and results of laboratory testing for *Sp* infection in Jingzhou, China from April 2010 to September 2012.\
CSF, cerebrospinal fluid; SARI, severe acute respiratory infection; *Sp*, *Streptococcus pneumoniae*.](pone.0201312.g001){#pone.0201312.g001}

Characteristics of patients with *Sp* infection {#sec015}
-----------------------------------------------

Of the 118 patients with *Sp* infection, 57% were aged ≥65 years. Cough (85%), temperature ≥38°C (65%), and sputum production (60%) were the most common symptoms and signs. None of the patients with confirmed *Sp* infection were vaccinated with PCV 7, 23-valent pneumococcal polysaccharide vaccine, or seasonal influenza vaccine. Nearly 100% patients received antibiotics during hospitalization. Forty patients (34%) were treated with corticosteroid, and 8 (80%) were meningitis cases. 56 patients (48%) were also treated with oxygen treatment. Eighteen *Sp* patients were admitted to an intensive care unit. Two patients (pneumonia case) died during hospitalization, and no additional patients died within 30 days after discharge. ([Table 1](#pone.0201312.t001){ref-type="table"})

10.1371/journal.pone.0201312.t001

###### Characteristics of patients with invasive *Sp*^+^ infection from four surveillance hospitals in Jingzhou, China, April 2010 to September 2012.

![](pone.0201312.t001){#pone.0201312.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                               All *Sp* patients\   Aged\<5 years\   5≤Aged\<65 years\   Aged≥65 years\
                                                               (N = 118)\           (N = 9)\         (N = 42)\           (N = 67)\
                                                               \[n, (%)\]           \[n, (%)\]       \[n, (%)\]          \[n, (%)\]
  ------------------------------------------------------------ -------------------- ---------------- ------------------- ----------------
  Male sex                                                     70 (59)              5 (56)           24 (57)             41 (61)

  Age, Median \[IQR, years\]                                   68 \[46--78\]        2 \[1--3\]       48 \[31--59\]       77 \[71--82\]

  Age group                                                                                                              

    \<5 year                                                   9 (8)                9 (64)           \-                  \-

    5--17 years                                                5 (4)                \-               5 (36)              \-

    18--49 years                                               16 (14)              \-               16 (15)             \-

    50--64 years                                               21 (18)              \-               21 (20)             \-

    ≥ 65 years                                                 67 (57)              \-               \-                  67(64)

  Underlying chronic medical conditions                                                                                  

      Any                                                      59 (50)              0 (0)            13 (31)             46 (69)

      Chronic bronchitis                                       20 (17)              0 (0)            3 (7)               17 (25)

      Hypertension                                             20 (17)              0 (0)            3 (7)               17 (25)

      Chronic obstructive pulmonary disease                    13 (11)              0 (0)            2 (5)               11 (16)

      Cardiovascular disease                                   13 (11)              0 (0)            0 (0)               13 (13)

      Asthma                                                   11 (9)               0 (0)            3 (7)               8 (12)

      Diabetes                                                 6 (5)                0 (0)            0 (0)               6 (6)

      Renal dysfunction                                        1 (0.8)              0 (0)            0 (0)               1 (1)

  Symptoms and signs at hospital admission                                                                               

      Cough                                                    100 (85)             6 (67)           31 (74)             63 (94)

      Temperature ≥38°C                                        77 (65)              9 (100)          29 (69)             39 (58)

      Sputum Production                                        71 (60)              1 (11)           19 (45)             51 (76)

      Sore throat                                              13 (11)              0 (0)            10 (24)             3 (5)

      Documented tachypnea                                     13 (11)              0 (0)            5 (12)              8 (12)

      Runny nose                                               9 (8)                2 (22)           2 (5)               5 (8)

      Difficulty breathing                                     9 (8)                1 (11)           4 (10)              4 (6)

      Chest pain                                               7 (6)                0 (0)            4 (10)              3 (5)

      Hemoptysis                                               4 (3)                0 (0)            2 (5)               2 (3)

      Diarrhea                                                 3 (3)                0 (0)            2 (5)               1 (2)

      Disturbance of consciousness                             3 (3)                1 (11)           2 (5)               0 (0)

      Vomiting                                                 2 (2)                0 (0)            1 (2)               1 (2)

      Abdominal pain                                           1 (0.8)              0 (0)            1 (2)               0 (0)

  Time interval                                                                                                          

      From illness onset to hospital admission \[IQR, days\]   4 \[1--7\]           2 \[1--5\]       4 \[2--7\]          4 \[1--7\]

      Length of stay in hospital \[IQR, days\]                 10 \[6--15\]         6 \[4--8\]       11 \[6--18\]        11 \[6--15\]

  Treatment                                                                                                              

      Received antiviral drugs                                 2 (2)                0 (0)            2 (5)               0 (0)

      Received antibiotics during hospitalization              117 (99)             9 (100.0)        41 (98)             67 (100)

      Received antibiotics before hospitalization              45/89 (51)           2/4 (50)         20/32 (63)          23/53 (43)

      Received corticosteroid during hospitalization           40 (34)              4 (44)           11 (26)             25 (37)

      Received oxygen treatment                                56 (48)              2 (22)           13 (31)             41 (61)

      Received mechanical ventilation                          5 (4)                1 (11)           0 (0)               4 (6)

  Complications                                                                                                          

      Respiratory failure                                      6 (5)                0 (0)            1 (2)               5 (8)

      Cardiac failure                                          4 (3)                0 (0)            0 (0)               4 (6)

      Hepatic dysfunction                                      2 (2)                0 (0)            2 (5)               0 (0)

         Renal dysfunction                                     2 (2)                0 (0)            0 (0)               2 (3)

         Neurologic disorders                                  2 (2)                0 (0)            2 (5)               0 (0)

         ARDS                                                  1 (0.8)              0 (0)            0 (0)               1 (2)

  Clinical severity                                                                                                      

      Pneumonia                                                84 (72)              4 (44)           27 (64)             53 (79)

      Meningitis                                               10 (8)               2 (22)           8 (19)              0 (0)

      ICU                                                      18 (15)              2 (22)           7 (17)              9 (13)

      Death                                                    2 (2)                0 (0)            0 (0)               2 (3)
  ---------------------------------------------------------------------------------------------------------------------------------------

ARDS, acute respiratory distress syndrome; ICU, intensive care unit; IQR, interquartile range; SARI, severe acute respiratory infection; *Sp*, *Streptococcus pneumoniae*.

SARI patients with laboratory confirmation of *Sp* infection were older (median 70 years versus 23 years), and more often had at least one chronic medical condition (52% versus 29%), including chronic bronchitis, hypertension, chronic obstructive pulmonary disease, cardiovascular disease and asthma (p\<0.05 for those comparisons) when compared with *Sp*-negative SARI patients. Patients with *Sp* detected were also more likely to have cough (p\<0.001) and sputum production (p\<0.001). These patients were less likely to have received seasonal influenza vaccine (p = 0.010) or to have received antibiotics before hospitalization (p = 0.048). During hospitalization, patients with *Sp* detected more often had pneumonia or respiratory failure diagnosed, more often received oxygen treatment and mechanical ventilation ([Table 2](#pone.0201312.t002){ref-type="table"}), and had longer hospital stays (p = 0.003)

10.1371/journal.pone.0201312.t002

###### Characteristics of SARI patients with *Sp*^+^ or *Sp*^-^ from four surveillance hospitals in Jingzhou, China, April 2010 to September 2012.

![](pone.0201312.t002){#pone.0201312.t002g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                               *Sp* Detected\   *Sp* Not Detected\   *p-*Value[^\*^](#t002fn001){ref-type="table-fn"}
                                                               (N = 108)\       (N = 3613)\          
                                                               \[n, (%)\]       \[n, (%)\]           
  ------------------------------------------------------------ ---------------- -------------------- --------------------------------------------------
  Male sex                                                     63 (58)          2167 (60)            0.734

  Age, Median \[IQR, years\]                                   70 \[56--78\]    23 \[3--64\]         **\<0.001**

  Age group                                                                                          **\<0.001**

    \<5 year                                                   7 (7)            1178 (33)            

    5--17 years                                                4 (4)            532 (15)             

    18--49 years                                               10 (9)           544 (15)             

    50--64 years                                               20 (19)          518 (14)             

    ≥ 65 years                                                 67 (62)          841 (23)             

  Underlying chronic medical conditions                                                              

      Any                                                      56 (52)          1039 (29)            **\<0.001**

      Chronic bronchitis                                       20 (19)          249 (7)              **\<0.001**

      Hypertension                                             19 (18)          388 (11)             **0.024**

      Chronic obstructive pulmonary disease                    13 (12)          255 (7)              **0.048**

      Cardiovascular disease                                   13 (12)          214 (6)              **0.009**

      Asthma                                                   11 (10)          104 (3)              **0.001**

      Diabetes                                                 6 (6)            101 (3)              0.131

      Renal dysfunction                                        1 (1)            43 (1)               0.795

  Symptoms and signs at hospital admission                                                           

      Cough                                                    98 (91)          2720 (75)            **\<0.001**

      Temperature ≥38°C                                        69 (64)          1946 (54)            0.112

      Sputum Production                                        70 (65)          1312 (36)            **\<0.001**

      Documented tachypnea                                     13 (12)          260 (7)              0.057

      Sore throat                                              12 (11)          469 (13)             0.569

      Runny nose                                               9 (8)            343 (10)             0.685

      Difficulty breathing                                     8 (7)            161 (5)              0.180

      Chest pain                                               7 (7)            128 (4)              0.144

      Hemoptysis                                               4 (4)            77 (2)               0.313

  Time interval                                                                                      

      From illness onset to hospital admission \[IQR, days\]   4 \[1--7\]       4 \[1--7\]           0.385

      Length of stay in hospital \[IQR, days\]                 10 \[6--15\]     7 \[5--11\]          **0.003**

  Vaccination                                                                                        

      PCV7                                                     0 (0)            16/1636 (1)          0.090

      PPV23                                                    0 (0)            24/1943 (1)          0.073

      Seasonal influenza vaccine                               0 (0)            95/2061 (5)          **0.010**

  Treatment                                                                                          

      Received antiviral drugs                                 2 (2)            19 (1)               0.148

      Received antibiotics during hospitalization              108 (100)        3586 (99)            0.198

      Received antibiotics before hospitalization              42/83 (51)       1609/2594 (62)       **0.048**

      Received corticosteroid during hospitalization           32 (30)          786 (22)             0.051

      Received oxygen treatment                                50 (47)          758 (21)             **\<0.001**

          Received mechanical ventilation                      4 (8)            31 (4)               **0.021**

  Complications                                                                                      

        Respiratory failure                                    6 (6)            79 (2)               **0.049**

        Cardiac failure                                        4 (4)            59 (2)               0.153

        Renal dysfunction                                      2 (2)            26 (1)               0.255

        ARDS                                                   1 (1)            21 (1)               0.670

        Hepatic dysfunction                                    0 (0)            42 (1)               0.115

        Neurologic disorders                                   0 (0)            19 (1)               0.290

  Clinical severity                                                                                  

      Pneumonia                                                83 (77)          1173 (33)            **\<0.001**

      ICU                                                      12 (11)          0 (0)                0.628

      Death                                                    2 (2)            27/3612 (1)          0.272
  -----------------------------------------------------------------------------------------------------------------------------------------------------

\*The P-values are comparisons between "*Sp* detected" and "*Sp* not detected".

ARDS, acute respiratory distress syndrome; ICU, intensive care unit; IQR, interquartile range; PCV7, 7-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide; SARI, severe acute respiratory infection; *Sp*, *Streptococcus pneumoniae*.

Laboratory confirmed *Sp* meningitis patients more frequently had liver dysfunction (p = 0.019), an elevated temperature ≥38°C (p = 0.047), received corticosteroids during their hospital stay (p = 0.039), and were admitted to the ICU during hospitalization (p = 0.013) ([Table 3](#pone.0201312.t003){ref-type="table"}) when compared with *Sp* negative meningitis patients.

10.1371/journal.pone.0201312.t003

###### Characteristics of meningitis patients with *Sp*^+^ or *Sp*^-^ from four surveillance hospitals in Jingzhou, China, April 2010 to September 2012.

![](pone.0201312.t003){#pone.0201312.t003g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                               *Sp* Detected\   *Sp* Not Detected\   *p-*Value[^\*^](#t003fn001){ref-type="table-fn"}
                                                               (N = 10)\        (N = 142)\           
                                                               \[n, (%)\]       \[n, (%)\]           
  ------------------------------------------------------------ ---------------- -------------------- --------------------------------------------------
  Male sex                                                     7 (70)           79 (56)              0.367

  Age, Median \[IQR, years\]                                   33 \[13--44\]    32 \[14--49\]        0.648

  Age group                                                                                          0.263

    \<5 year                                                   2 (20)           18 (13)              

    5--17 years                                                1 (10)           26 (18)              

    18--49 years                                               6 (60)           65 (46)              

    50--64 years                                               1 (10)           24 (17)              

    ≥ 65 years                                                 0 (0)            9 (9)                

  Underlying chronic medical conditions                                                              

      Any                                                      3 (30)           12 (8)               0.063

      Hypertension                                             1 (10)           5 (4)                0.384

      Liver dysfunction                                        1 (10)           0 (0)                **0.019**

      Stroke                                                   0 (0)            2 (1)                0.601

      Asthma                                                   0 (0)            2 (1)                0.601

  Symptoms and signs at hospital admission                                                           

      Temperature ≥38°C                                        8 (80)           69 (49)              **0.047**

      Nuchal rigidity                                          7 (70)           66 (47)              0.146

      Kernig sign                                              5 (50)           30 (21)              0.053

      Disturbance of consciousness                             3 (30)           23 (16)              0.297

      Brudzinski\'s sign                                       2 (20)           15 (11)              0.400

      Twitch                                                   2 (20)           10 (7)               0.204

      Cough                                                    2 (20)           30 (21)              0.932

      Sputum Production                                        1 (10)           9 (6)                0.672

      Sore throat                                              1 (10)           17 (12)              0.849

      Difficulty breathing                                     1 (10)           2 (1)                0.161

      Diarrhea                                                 1 (10)           3 (2)                0.234

      Vomiting                                                 1 (10)           18 (13)              0.799

      Abdominal pain                                           1 (10)           4 (3)                0.309

  Time interval                                                                                      

      From illness onset to hospital admission \[IQR, days\]   4 \[2--20\]      4 \[1--7\]           0.279

      Length of stay in hospital \[IQR, days\]                 26 \[8--29\]     12 \[6--19\]         0.089

  Vaccination                                                                                        

      PCV7                                                     0 (0)            1/41 (2)             0.699

      PPV23                                                    0 (0)            1/43 (2)             0.750

      Seasonal influenza vaccine                               0 (0)            1/78 (1)             0.113

  Treatment                                                                                          

      Received antiviral drugs                                 0 (0)            0 (0)                \-

      Received antibiotics during hospitalization              9 (90)           130 (92)             0.868

      Received antibiotics before hospitalization              3/6 (50)         41/90 (46)           0.956

      Received corticosteroid during hospitalization           8 (80)           67 (47)              **0.039**

      Received oxygen treatment                                6 (60)           55 (39)              0.190

          Received mechanical ventilation                      1 (10)           2 (1)                0.161

  Complications                                                                                      

      Neurologic disorders                                     2 (20)           19 (13)              0.577

      Hepatic dysfunction                                      2 (20)           5 (4)                0.062

      Shock                                                    0 (0)            1 (1)                0.712

      Tympanitis                                               0 (0)            0 (0)                \-

  Clinical severity                                                                                  

      ICU                                                      6 (60)           0 (0)                **0.013**

      Death                                                    0 (0)            1 (1)                0.712
  -----------------------------------------------------------------------------------------------------------------------------------------------------

\*The P-values are comparisons between "*Sp* detected" and "*Sp* not detected".

ICU, intensive care unit; IQR, interquartile range; PCV7, 7-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide; SARI, severe acute respiratory infection; *Sp*, *Streptococcus pneumoniae*.

Distribution of serotype {#sec016}
------------------------

Of 16 isolates serotyped, 2 were non-typeable, 2 each were 14, 12, 3 and 1, and one each was serotype 19F, 4, 5, 9V, 15 and 18C. For cases \<5 years old, serotypes were 3, 4, 12, 14, 15 and 18; for cases 5--64 years old, serotypes 1, 12, 18C; and for cases ≥65, serotypes 3, 5, 9V and 14. The total coverage levels were 42%, 63% and 77% for PCV7, PCV10, and PCV13, respectively. Additionally, for persons aged \<5 years, coverage levels were 51%, 51%, 68% for PCV7, PCV10 and PCV13. For persons aged ≥ 5 years, vaccine coverage was 38%, 75%, 88% for PCV7, PCV10 and PCV13. ([Fig 2](#pone.0201312.g002){ref-type="fig"})

![Proportion and cumulative distribution of serotype from *Sp*^+^ patients in Jingzhou, China from April 2010 to September 2012.\
Panel A: All *Sp*^+^ patients. Panel B: *Sp*^+^ patients aged\<5 years. Panel C: *Sp*^+^ patients aged≥5 years.](pone.0201312.g002){#pone.0201312.g002}

Discussion {#sec017}
==========

In this large, prospective study in China, *Sp* was infrequently identified as the cause of pneumonia and meningitis, and few patients were vaccinated against *S*p infection.

Multiple studies have been published in China documenting *Sp* as a common cause of respiratory infection in children and adults, but most relied on the use of non-sterile specimens, such as oro-pharyngeal or naso-pharyngeal swabs\[[@pone.0201312.ref005], [@pone.0201312.ref009]--[@pone.0201312.ref012]\]. Our study, in contrast, is the first large study in China to prospectively enroll patients with a broad case definition of severe acute respiratory infection or meningitis and to test specimens from sterile sites. *Sp* is considered the most common cause of bacterial community acquired pneumonia (CAP)\[[@pone.0201312.ref013]\], and may cause 30--50% of pneumonia requiring hospitalization in Europe and United States\[[@pone.0201312.ref014]\]. Although 72% of patients with *Sp* detected in our study were diagnosed with pneumonia, only 7% of patients diagnosed with pneumonia had *Sp* detected. *Sp* is also a common cause of meningitis globally\[[@pone.0201312.ref015]\], and was the most common cause of bacterial meningitis in one previous population-based study in China\[[@pone.0201312.ref016]\]. Nevertheless, *Sp* was only identified in 6% of patients who met our case definition of meningitis.

The low rate of *Sp* detection in our study may be due to the expansive case definition. First, we intentionally enrolled a broad cross-section of patients with severe illness, which resulted in many patients in whom *Sp* infection was unlikely to be detected, such as adults aged 18--64 years. Second, over 50% of patients received antibiotics before hospitalization, increasing the likelihood that bacterial cultures of blood and CSF would be negative\[[@pone.0201312.ref017]--[@pone.0201312.ref020]\]. Third, we embedded the study within routine clinical practice, which could have limited the quality of specimen collection and testing. The optimum time for specimen collection is actually before symptoms occur\[[@pone.0201312.ref021]\], but in our study, specimens were not collected until hospitalization, which occurred a median of 2 days after symptom onset. Lastly, the methods to detect pneumococcus, such as real-time PCR or Binax NOW® antigen test, can dramatically increase the detection of pneumococcus, especially in thoese already having received antibiotics. Although real--time PCR is a more sensitive method of detecting invasive pneumococcal disease, bacterial culture is the standard diagnostic method that has been used in local hospitals for years and there were insufficient funds to support this method.

WHO and ACIP recommend the use of conjugate pneumooccal vaccine to prevent invasive disease in children and the elderly\[[@pone.0201312.ref002], [@pone.0201312.ref022]\]. We found that no patients with *Sp* detected reported previous *Sp* vaccination. *Sp* vaccination is uncommon in China, because it is not included in the national immunization program for children or adults, to the relatively low awareness of the disease, and to the high out-of-pocket charges for *Sp* vaccine\[[@pone.0201312.ref023]\]. In our study, the median age of patients with *Sp* was 68 years, consistent with studies indicating the elderly are at high risk for invasive pneumococcal disease and can benefit from vaccination\[[@pone.0201312.ref024]\].

Despite their age and the frequency of comorbid medical conditions, few patients with *Sp* died in our study. There are other reasons such as prompt and supportive medical care, but one possibility is that early, widespread use of antibiotics prevented death\[[@pone.0201312.ref025]\]. We found that PCV13, which has recently been licensed in China, would have covered 77% of the *Sp* infections identified detected in our study, including 68% of those in people aged \<5 years and 88% in those aged ≥5 years. WHO recommends that pneumococcal conjugate vaccine be included in national childhood immunization programs, but does not make a similar recommendation for the elderly\[[@pone.0201312.ref002]\]. Given the population-level and individual harms associated with widespread antibiotic use, the documented benefits of pneumococcal vaccination in other settings\[[@pone.0201312.ref001], [@pone.0201312.ref021], [@pone.0201312.ref026], [@pone.0201312.ref027]\], and the expected serotype coverage of PCV13 in China, further work is needed to expand access to pneumococcal vaccination in China, both among children and potentially among the elderly.

In China, inappropriate use of antibiotics is a widespread and serious problem\[[@pone.0201312.ref028], [@pone.0201312.ref029]\]. In our study, over 50% of enrolled patients received antibiotic treatment before hospitalization, and nearly 100% of enrolled patients received antibiotics during hospitalization, even though few had a documented bacterial infection. Widespread use of antibiotics may increase resistance and lead to individual health complications. China has recently begun programs to promote judicious prescribing of antibiotics and to restrict pharmacies from dispensing antibiotics without a doctor's prescription. Additionally, corticosteroid treatment has been used widely as adjunctive treatment for adults with bacterial meningitis\[[@pone.0201312.ref030]\]. About 80% of meningitis patients with confirmed *Sp* infection received corticosteroid treatment. Corticosteroid treatment has been independently associated with favorable outcomes and survival in patients with pneumococcal and non-pneumococcal meningitis\[[@pone.0201312.ref031], [@pone.0201312.ref032]\].

In addition to the limitations noted above, our study was also limited to only one city, did not enroll outpatients, and relied on routinely collected data, albeit prospectively, from medical records. It is possible that we, therefore, under-estimated incidence and disease burden. Nevertheless, our study adds to the limited literature about *Sp* infections in China and provides further data to support the potential benefits of *Sp* vaccination among children and the elderly in China. Furthermore, the characterization of *Sp* isolates and infections in this study can contribute to more rapid detection and control of *Sp* outbreaks in China, and thereby contribute to enhanced global health security.
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